Tenpoint Therapeutics Secures $235M, Prepares YUVEZZI Launch for Presbyopia
February 2, 2026, 9:36 pm
Location: United States
Employees: 11-50
Founded date: 2020
Total raised: $317.72M
Tenpoint Therapeutics secured $235 million in new capital. This robust funding fuels the impending launch of YUVEZZI. YUVEZZI is an FDA-approved, first-of-its-kind dual-agent eye drop. It targets presbyopia, a widespread aging vision condition affecting billions. The financing combines an $85 million Series B round, led by major investors, and a $150 million credit facility from Hercules Capital. This capital infusion significantly strengthens Tenpoint’s balance sheet. It accelerates YUVEZZI's commercialization strategy. The product is set for an early Q2 market debut, marking a pivotal moment in global ocular health innovation.
Tenpoint Therapeutics, a prominent biotechnology firm, recently closed a substantial financing round. The company secured $235 million. This capital infusion targets the commercial launch of YUVEZZI. YUVEZZI is their novel presbyopia treatment. Its market entry is imminent. This funding marks a significant milestone for the London and Seattle-based company.
The financing comprises two distinct components. An $85 million Series B preferred stock financing was completed. This equity round attracted leading global investors. Janus Henderson spearheaded the Series B. EQT Nexus, Hillhouse, and British Business Bank also provided substantial backing. Existing investors continued their support. These included EQT Life Sciences, Sofinnova Partners, and F-Prime. Eight Roads, Qiming Venture Partners USA, AdBio, and Wille also participated. This broad investor syndicate signals strong confidence in Tenpoint's vision.
Parallel to the Series B, Tenpoint secured a $150 million senior secured term loan facility. Hercules Capital provided this non-dilutive financing. This facility further fortifies the company’s financial standing. It offers significant capital without issuing additional shares. This structure protects existing shareholder value. The combined capital raises total $235 million. This sum strengthens the company's balance sheet. It ensures ample resources for the commercial launch of YUVEZZI.
YUVEZZI represents a significant breakthrough in ophthalmology. It is a dual-agent eye drop. The solution combines carbachol and brimonidine tartrate. This unique formulation targets presbyopia. Presbyopia is a common age-related vision condition. It causes difficulty with near vision. The U.S. FDA recently approved YUVEZZI. This approval positions YUVEZZI as the only dual-agent, once-daily eye drop for presbyopia. This distinction is crucial for market differentiation.
The global market for presbyopia treatment is vast. Nearly 2 billion people worldwide experience presbyopia. In the United States alone, approximately 128 million individuals are affected. This substantial patient population underscores the market potential for effective treatments. YUVEZZI offers a new option for these millions. It addresses a daily frustration for many.
Tenpoint Therapeutics describes itself as a global commercial biotechnology company. Its mission focuses on rejuvenating vision. It targets the aging eye. The company develops groundbreaking treatments. These treatments aim to innovate in ocular health. YUVEZZI is central to this mission. It directly addresses a widespread need.
Company leadership expresses optimism. They acknowledge investor confidence. The financing reflects belief in YUVEZZI’s potential. It is a differentiated option for millions. The strengthened balance sheet facilitates a robust market launch. Early Q2 is the target for YUVEZZI’s debut. This timing aligns perfectly with the FDA approval. It creates an ideal launch point.
YUVEZZI’s profile includes favorable safety and tolerability. This reinforces its commercial potential. Patients and providers are expected to embrace the new treatment. The leadership team possesses extensive ophthalmology experience. They have executed key milestones. These steps led to commercialization. The team is well-positioned for success.
The development and commercialization of YUVEZZI represent years of scientific effort. This product offers a new standard of care. It provides an effective, convenient solution. Patients can regain clearer near vision. The once-daily application simplifies treatment regimens. This enhances patient adherence.
This funding ensures Tenpoint's readiness. It supports robust manufacturing. It allows comprehensive marketing campaigns. It secures widespread distribution channels. The company aims for broad market penetration. They seek to reach all eligible patients. Their goal is to improve daily life for those with presbyopia.
The biotechnology sector constantly evolves. Innovation drives progress. Tenpoint Therapeutics stands at the forefront of ocular innovation. YUVEZZI is a testament to this commitment. It offers a new pathway for aging eyes. It promises to rejuvenate vision for many. This investment fuels that promise. It prepares for a significant impact on global vision care.
Tenpoint Therapeutics, a prominent biotechnology firm, recently closed a substantial financing round. The company secured $235 million. This capital infusion targets the commercial launch of YUVEZZI. YUVEZZI is their novel presbyopia treatment. Its market entry is imminent. This funding marks a significant milestone for the London and Seattle-based company.
The financing comprises two distinct components. An $85 million Series B preferred stock financing was completed. This equity round attracted leading global investors. Janus Henderson spearheaded the Series B. EQT Nexus, Hillhouse, and British Business Bank also provided substantial backing. Existing investors continued their support. These included EQT Life Sciences, Sofinnova Partners, and F-Prime. Eight Roads, Qiming Venture Partners USA, AdBio, and Wille also participated. This broad investor syndicate signals strong confidence in Tenpoint's vision.
Parallel to the Series B, Tenpoint secured a $150 million senior secured term loan facility. Hercules Capital provided this non-dilutive financing. This facility further fortifies the company’s financial standing. It offers significant capital without issuing additional shares. This structure protects existing shareholder value. The combined capital raises total $235 million. This sum strengthens the company's balance sheet. It ensures ample resources for the commercial launch of YUVEZZI.
YUVEZZI represents a significant breakthrough in ophthalmology. It is a dual-agent eye drop. The solution combines carbachol and brimonidine tartrate. This unique formulation targets presbyopia. Presbyopia is a common age-related vision condition. It causes difficulty with near vision. The U.S. FDA recently approved YUVEZZI. This approval positions YUVEZZI as the only dual-agent, once-daily eye drop for presbyopia. This distinction is crucial for market differentiation.
The global market for presbyopia treatment is vast. Nearly 2 billion people worldwide experience presbyopia. In the United States alone, approximately 128 million individuals are affected. This substantial patient population underscores the market potential for effective treatments. YUVEZZI offers a new option for these millions. It addresses a daily frustration for many.
Tenpoint Therapeutics describes itself as a global commercial biotechnology company. Its mission focuses on rejuvenating vision. It targets the aging eye. The company develops groundbreaking treatments. These treatments aim to innovate in ocular health. YUVEZZI is central to this mission. It directly addresses a widespread need.
Company leadership expresses optimism. They acknowledge investor confidence. The financing reflects belief in YUVEZZI’s potential. It is a differentiated option for millions. The strengthened balance sheet facilitates a robust market launch. Early Q2 is the target for YUVEZZI’s debut. This timing aligns perfectly with the FDA approval. It creates an ideal launch point.
YUVEZZI’s profile includes favorable safety and tolerability. This reinforces its commercial potential. Patients and providers are expected to embrace the new treatment. The leadership team possesses extensive ophthalmology experience. They have executed key milestones. These steps led to commercialization. The team is well-positioned for success.
The development and commercialization of YUVEZZI represent years of scientific effort. This product offers a new standard of care. It provides an effective, convenient solution. Patients can regain clearer near vision. The once-daily application simplifies treatment regimens. This enhances patient adherence.
This funding ensures Tenpoint's readiness. It supports robust manufacturing. It allows comprehensive marketing campaigns. It secures widespread distribution channels. The company aims for broad market penetration. They seek to reach all eligible patients. Their goal is to improve daily life for those with presbyopia.
The biotechnology sector constantly evolves. Innovation drives progress. Tenpoint Therapeutics stands at the forefront of ocular innovation. YUVEZZI is a testament to this commitment. It offers a new pathway for aging eyes. It promises to rejuvenate vision for many. This investment fuels that promise. It prepares for a significant impact on global vision care.